GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cryo-Cell International Inc (AMEX:CCEL) » Definitions » Piotroski F-Score

Cryo-Cell International (Cryo-Cell International) Piotroski F-Score

: 5 (As of Today)
View and export this data going back to . Start your Free Trial

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Cryo-Cell International has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Cryo-Cell International's Piotroski F-Score or its related term are showing as below:

CCEL' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of Cryo-Cell International was 8. The lowest was 3. And the median was 6.


Cryo-Cell International Piotroski F-Score Historical Data

The historical data trend for Cryo-Cell International's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryo-Cell International Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 8.00 4.00 6.00 5.00

Cryo-Cell International Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 7.00 7.00 8.00 5.00

Competitive Comparison

For the Medical Care Facilities subindustry, Cryo-Cell International's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryo-Cell International Piotroski F-Score Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Cryo-Cell International's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Nov23) TTM:Last Year (Nov22) TTM:
Net Income was 0.767 + 0.221 + 0.681 + -11.19 = $-9.52 Mil.
Cash Flow from Operations was 1.644 + 1.989 + 1.942 + 3.344 = $8.92 Mil.
Revenue was 7.824 + 7.773 + 7.87 + 7.877 = $31.34 Mil.
Gross Profit was 5.757 + 5.63 + 5.714 + 5.801 = $22.90 Mil.
Average Total Assets from the begining of this year (Nov22)
to the end of this year (Nov23) was
(64.888 + 66.134 + 68.758 + 69.796 + 61.221) / 5 = $66.1594 Mil.
Total Assets at the begining of this year (Nov22) was $64.89 Mil.
Long-Term Debt & Capital Lease Obligation was $9.28 Mil.
Total Current Assets was $9.45 Mil.
Total Current Liabilities was $20.86 Mil.
Net Income was 0.832 + 0.635 + 0.467 + 0.838 = $2.77 Mil.

Revenue was 7.259 + 7.633 + 7.681 + 7.764 = $30.34 Mil.
Gross Profit was 5.155 + 5.432 + 5.332 + 5.625 = $21.54 Mil.
Average Total Assets from the begining of last year (Nov21)
to the end of last year (Nov22) was
(60.662 + 54.808 + 55.395 + 66.765 + 64.888) / 5 = $60.5036 Mil.
Total Assets at the begining of last year (Nov21) was $60.66 Mil.
Long-Term Debt & Capital Lease Obligation was $8.89 Mil.
Total Current Assets was $9.61 Mil.
Total Current Liabilities was $19.48 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Cryo-Cell International's current Net Income (TTM) was -9.52. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Cryo-Cell International's current Cash Flow from Operations (TTM) was 8.92. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Nov22)
=-9.521/64.888
=-0.14672975

ROA (Last Year)=Net Income/Total Assets (Nov21)
=2.772/60.662
=0.04569582

Cryo-Cell International's return on assets of this year was -0.14672975. Cryo-Cell International's return on assets of last year was 0.04569582. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Cryo-Cell International's current Net Income (TTM) was -9.52. Cryo-Cell International's current Cash Flow from Operations (TTM) was 8.92. ==> 8.92 > -9.52 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Nov23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Nov22 to Nov23
=9.282/66.1594
=0.14029752

Gearing (Last Year: Nov22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Nov21 to Nov22
=8.893/60.5036
=0.14698299

Cryo-Cell International's gearing of this year was 0.14029752. Cryo-Cell International's gearing of last year was 0.14698299. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Nov23)=Total Current Assets/Total Current Liabilities
=9.453/20.864
=0.45307707

Current Ratio (Last Year: Nov22)=Total Current Assets/Total Current Liabilities
=9.61/19.481
=0.49330117

Cryo-Cell International's current ratio of this year was 0.45307707. Cryo-Cell International's current ratio of last year was 0.49330117. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Cryo-Cell International's number of shares in issue this year was 8.287. Cryo-Cell International's number of shares in issue last year was 8.514. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=22.902/31.344
=0.73066616

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=21.544/30.337
=0.71015592

Cryo-Cell International's gross margin of this year was 0.73066616. Cryo-Cell International's gross margin of last year was 0.71015592. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Nov22)
=31.344/64.888
=0.48304771

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Nov21)
=30.337/60.662
=0.50009891

Cryo-Cell International's asset turnover of this year was 0.48304771. Cryo-Cell International's asset turnover of last year was 0.50009891. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+0+1+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Cryo-Cell International has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Cryo-Cell International  (AMEX:CCEL) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Cryo-Cell International Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Cryo-Cell International's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryo-Cell International (Cryo-Cell International) Business Description

Traded in Other Exchanges
Address
700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of Prepacyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. All the business activity of the group functions through the United States and it derives revenue from processing and testing fees and storage fees charged each year for storage and through sales of the Prepacyte CB units.
Executives
David Portnoy director, officer: Co-Chief Executive Officer C/O FOCUS FINANCIAL GROUP, 61 HARBOUR WAY, BAL HARBOUR FL 33154
George Gaines director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Jonathan H. Wheeler director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Brian L. Sheehy director 415 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Mark L. Portnoy director, officer: Co-Chief Executive Officer 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Harold D. Berger director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Arthur Ellis director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Mary J Nyberg 10 percent owner 455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Cdmj Nyberg Family Trust 10 percent owner 455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Jill M Taymans officer: VP, Finance, CFO
Oleg Mikulinsky officer: Chief Information Officer 700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Anthony Atala director 700 BROOKER CREEK BOULEVARD, OLDSMAR FL 34677
Scott G Christian director
Sung Won Sohn director 700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Michael W. Cho director C/O IOWA STATE UNIVERSITY, 1600 S. 16TH STREET, AMES IA 50011-1250